Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$1.19T+155.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Julie So-Young Kim
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 47,029
- Beta
- 0.09
- Country
- JP
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 1.40
Financials
Revenue
$1.19T+155.3%Net Income
$192.43B+365.1%EBITDA
$326.94B+222.5%Free Cash Flow
$212.65BEPS (diluted)
$59.96+127.4%Shares Outstanding (diluted)
3.21B+104.5%Operating Expenses
$442.94BCash & Debt
$454.40BReturn of Capital
$7.58BRevenue by Segment (annual)
$4.51TDividend per Share
$0.40Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.51T | $-152.39B | $-48.37 |
| 2024 | $4.58T | $107.93B | $34.17 |
| 2023 | $4.26T | $144.07B | $46.05 |
| 2022 | $4.03T | $317.02B | $102.15 |
| 2021 | $3.57T | $230.06B | $73.57 |
| 2020 | $3.20T | $376.00B | $120.36 |
| 2019 | $3.29T | $44.24B | $14.21 |
| 2018 | $2.10T | $109.13B | $34.78 |
| 2017 | $1.77T | $186.89B | $119.68 |
| 2016 | $1.73T | $114.94B | $73.58 |
| 2015 | $1.81T | $80.17B | $51.13 |
| 2014 | $1.78T | $-145.78B | $-46.47 |
| 2013 | $1.69T | $106.66B | $67.55 |
| 2012 | $1.56T | $131.24B | $94.11 |
Valuation
TAKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+400.00%Social Signal Score
Mentions (13)
- Newsbusinesswire.com·10d ago·Neutral
Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States.
View source ↗ - Newsseekingalpha.com·23d ago·Negative
Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace major drug revenues and current valuation. Operating margin improved to 17% due to lower amortization, but operating cash flow declined to $2.74B, highlighting weak underlying cash generation. New products like Mimrylo and Orzeyful are slow to ramp and currently contribute minimally, while Entyvio remains the key revenue driver
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to support profitability.
View source ↗ - Newsseekingalpha.com·24d ago·Positive
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript
View source ↗ - Newsbusinesswire.com·24d ago·Positive
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide), progress in the regulatory review of zasocitinib, and additional clinical evidence across the late-stage pipeli…
View source ↗ - Newsbusinesswire.com·39d ago·Neutral
… Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying…
View source ↗ - Newsseekingalpha.com·40d ago·Negative
Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline Takeda gets its prior buy rating reaffirmed. Positive factors are recent drug approval, robust future pipeline, global reach, and an investment-grade rating. TAK serves several clinical areas, filling specific medical needs.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbusinesswire.com·69d ago·Negative
…n Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) in…
View source ↗ - Newsreuters.com·86d ago·Negative
US FDA approves Takeda, Protagonist's drug for rare blood cancer The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said on Friday.
View source ↗ - Newsbusinesswire.com·90d ago·Positive
… in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease …
View source ↗ - Newszacks.com·96d ago·Neutral
Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newszacks.com·97d ago·Positive
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
View source ↗
Earnings
Thu, Jan 28(in 2 months)
Consensus estimate $0.14 per share
Typical surprise -61.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$0.39 vs $0.31beat
- Thu, Jul 30$0.23 vs $0.17beat
- Wed, May 13$-0.05 vs $0.21miss
- Thu, Jan 29$0.21 vs $0.55miss
- Thu, Oct 30$-0.02 vs $0.44miss
- Wed, Jul 30$0.52 vs $0.47beat
Estimates and results for TAK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TAK officers and directors.
- Bought
- —
- Sold
- $15.2m
0 trades
22 trades
- Platford Giles Richardsold
- Bitetti Teresa Mariesold
- Duprey Lauren Rusckowskisold
- Plump Andrew Stewartsold
- Plump Andrew Stewartsold
- Greenway Nicola Deidre Petalsold
- Shannon Elaine Marysold
- Farajallah Awny Samaan Botrossold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (31d later)Buy$1,001 - $15,000
- Virginia Ann Foxxhouse · NC05 · disclosed Sep 5, 2023 (7d later)Sell$15,001 - $50,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (28d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Mar 20, 2023 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Buy$15,001 - $50,000
- Virginia Ann Foxxhouse · NC05 · disclosed Mar 3, 2023 (15d later)Buy$1,001 - $15,000
- Virginia Ann Foxxhouse · NC05 · disclosed Dec 6, 2022 (35d later)Buy$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Oct 20, 2019 (39d later)Sell$1,001 - $15,000
- Van Taylorhouse · TX03 · disclosed Apr 15, 2019 (21d later)Sell$15,001 - $50,000
- Greg Gianfortehouse · MT00 · disclosed Jan 23, 2019 (33d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
